AdaptHealth (NASDAQ:AHCO) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 25.7%
AdaptHealth Corp. (NASDAQ:AHCO) reported Q2 CY2026 revenue of $740.3 million, down 7.5% year on year, below analyst estimates. Full-year revenue guidance was $2.87 billion at the midpoint, 17.7% below consensus. GAAP EPS was a loss of $0.99, and the stock fell 25.7% to $8.05 after results.
How this was made
The 30-second read
Why it matters
Q2 revenue decline plus full-year revenue guidance materially below consensus, alongside a deeper GAAP loss and sharp same-day selloff, increases the probability of downward estimate revisions and near-term multiple compression.
Market read
This is a direct earnings and guidance miss with quantified shortfalls versus consensus and an immediate 25.7% stock drop, making it actionable for trading around estimate revisions.
What to watch
The text highlights margin deterioration (adjusted operating margin negative in Q2) but does not break out drivers (pricing, utilization, mix, or cost actions), which could change the forward outlook if clarified.
Background
AdaptHealth is a home medical equipment and services provider with a large US footprint, and the article frames its recent slowdown versus prior multi-year growth.
Ticker impact
AdaptHealth reported Q2 CY2026 revenue of $740.3M, down 7.5% YoY, and full-year guidance $2.87B midpoint 17.7% below estimates.
Bearish bias for the next several sessions, with volatility elevated around any follow-up guidance or analyst revisions.
The article provides concrete, time-sensitive datapoints: revenue decline, guidance materially below consensus, EPS loss of -$0.99, and an immediate 25.7% stock drop to $8.05.
Market effects
Weak results in home healthcare services can pressure sentiment toward similarly levered, margin-sensitive providers.
Primarily US healthcare services sentiment; limited direct regional spillover described.
No explicit global linkage beyond US analyst expectations and healthcare demand narrative.
Counterpoint
Despite the miss, the article notes analysts expect revenue growth of 12.1% over the next 12 months, suggesting a potential inflection if execution improves.
Key entities
- public_companyAdaptHealth Corp.
NASDAQ-listed home medical equipment and services provider reporting Q2 CY2026 results and full-year guidance.
- market_participantsWall Street analysts
Consensus reference for revenue and EPS estimates used to judge the miss and set expectations for forward revisions.
